[HTML][HTML] Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells
R Goto, S You, M Zaitsu, L Chatenoud… - American Journal of …, 2013 - Elsevier
The engineered Fc-nonbinding (crystallizable fragment-nonbinding) CD3 antibody has
lower mitogenicity and a precise therapeutic window for disease remission in patients with
type 1 diabetes. Before anti-CD3 can be considered for use in transplantation, the most
effective timing of treatment relative to transplantation needs to be elucidated. In this study
anti-CD3F (ab′) 2 fragments or saline were administered intravenously for 5 consecutive
days (early: d1–3 or delayed: d3–7) to mice transplanted with a cardiac allograft (H2 b-to-H2 …
lower mitogenicity and a precise therapeutic window for disease remission in patients with
type 1 diabetes. Before anti-CD3 can be considered for use in transplantation, the most
effective timing of treatment relative to transplantation needs to be elucidated. In this study
anti-CD3F (ab′) 2 fragments or saline were administered intravenously for 5 consecutive
days (early: d1–3 or delayed: d3–7) to mice transplanted with a cardiac allograft (H2 b-to-H2 …
